HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Characterization of a Na(+)-Ca(2+) exchanger in podocytes.

AbstractBACKGROUND:
Knowledge about Ca(2+) extrusion mechanisms in podocytes is limited. The aim of the study was to test whether a Na(+)-Ca(2+) exchanger (NCX) is present in differentiated podocytes and if so to examine its regulatory properties.
METHODS:
Intracellular Ca(2+) concentration ([Ca(2+)](i)) and intracellular pH were measured microspectrofluorometrically in single podocytes. Expression of NCX mRNA was studied by reverse transcription-polymerase chain reaction. NCX protein expression was investigated by immunocytochemistry.
RESULTS:
Substitution of extracellular Na(+) (from 145 to 0, 5, 10, 20, and 30 mM) with N-methyl-D-glucamine resulted in a Na(+) concentration-dependent, reversible increase of [Ca(2+)](i). Complete extracellular Na(+) substitution (0 Na(+)) increased [Ca(2+)](i) reversibly from 95+/-5 to 275+/-16 and back to 66+/-5 nM (n=205). Raising the intracellular Na(+) concentration by application of 50 micro M monensin increased [Ca(2+)](i) from 105+/-22 to 192+/-45 nM (n=12). The [Ca(2+)](i) response induced by a low Na(+) concentration required extracellular Ca(2+) and did not correlate with changes of intracellular pH. The effect was blocked by the NCX inhibitor benzamil (IC(50) approximately 100 nM). Neither flufenamate (100 micro M, n=6), a blocker of non-selective cation channels, nor Hoe 694 (1 micro M, n=6), an inhibitor of the Na(+)-H(+) exchanger, did significantly influence the [Ca(2+)](i) response induced by extracellular Na(+) depletion. Activation of protein kinase C (PKC) by short-term application (5 min) of phorbol 12-myristate-13-acetate (PMA; 10 nM, n=4; 100 nM, n=7) inhibited Na(+)-Ca(2+) exchange, whereas PKC inhibition by long-term incubation (24 h) with PMA (100 nM, n=9) or bisindolylmaleimide I (100 nM, n=11) both increased Na(+)-Ca(2+) exchange, respectively. Expression of NCX mRNA was detected both in cultured differentiated podocytes and in podocytes directly pulled off from glomeruli ex vivo. NCX protein expression was detected by immunocytochemistry. In a different series of experiments, we studied the potential involvement of the exchanger in podocyte injury induced by the aminonucleoside puromycin. Pre-treatment of podocytes with 0.3 mM puromycin for 24 h significantly reduced the [Ca(2+)](i) response induced by extracellular Na(+) depletion (n=56). Compared with mRNA expression of the housekeeping gene GAPDH, NCX mRNA expression was significantly reduced by puromycin.
CONCLUSION:
Our results demonstrate the presence of a Na(+)-Ca(2+) exchanger in podocytes and its regulation by PKC. Inhibition of Na(+)-Ca(2+) exchange by puromycin may contribute to podocyte injury in PAN nephrosis.
AuthorsKarl-Georg Fischer, Nils Jonas, Florian Poschenrieder, Clemens Cohen, Matthias Kretzler, Stefan Greiber, Hermann Pavenstädt
JournalNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (Nephrol Dial Transplant) Vol. 17 Issue 10 Pg. 1742-50 (Oct 2002) ISSN: 0931-0509 [Print] England
PMID12270979 (Publication Type: Journal Article)
Chemical References
  • RNA, Messenger
  • Sodium-Calcium Exchanger
  • benzamil
  • Puromycin Aminonucleoside
  • Amiloride
  • Sodium
  • Protein Kinase C
  • Calcium
Topics
  • Amiloride (analogs & derivatives, pharmacology)
  • Animals
  • Calcium (metabolism)
  • Cells, Cultured
  • Cytosol (metabolism)
  • Enzyme Activation (physiology)
  • Extracellular Space (metabolism)
  • Hydrogen-Ion Concentration
  • Kidney (cytology, metabolism)
  • Mice
  • Osmolar Concentration
  • Protein Kinase C (metabolism)
  • Puromycin Aminonucleoside (pharmacology)
  • RNA, Messenger (metabolism)
  • Sodium (metabolism)
  • Sodium-Calcium Exchanger (antagonists & inhibitors, drug effects, genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: